MXCTHealthcare · Medical DevicesThe 6 Wall Street analysts covering MaxCyte, Inc. hold a median 12-month price target of $4.5 — +341.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores MaxCyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Volatility (40): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MXCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +341.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | Craig-Hallum | Maintains | Buy | $7.00 → $5.00 |
| 11 Aug 2025 | BTIG | Downgrade | Neutral | — |
| 7 Aug 2025 | William Blair | Downgrade | Market Perform | — |
| 22 July 2025 | Stephens & Co. | Assumes | Overweight | $6.00 |
| 12 Mar 2025 | Stifel | Maintains | Buy | — |
| 23 Apr 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Mar 2024 | BTIG | Maintains | Buy | — |
| 13 Mar 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 29 Nov 2023 | Craig-Hallum | Initiates | Buy | — |
| 5 Oct 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 28 Mar 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 15 Aug 2022 | BTIG | Maintains | Buy | — |
| 24 Aug 2021 | BTIG | Initiates | Buy | — |
| 24 Aug 2021 | Cowen & Co. | Initiates | Outperform | — |
| 24 Aug 2021 | Stephens & Co. | Initiates | Overweight | — |
| 24 Aug 2021 | Stifel | Initiates | Buy | — |
| 24 Aug 2021 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MXCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, MaxCyte, Inc. returned −40.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 35% of US stocks
Cheaper than 80% of US stocks
Cheaper than 67% of US stocks
Higher than 13% of US stocks
Higher than 24% of US stocks
Higher than 89% of US stocks
Higher than 12% of US stocks
Higher than 5% of US stocks
Higher than 31% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MaxCyte, Inc. has a market value of $107.3M and an enterprise value of $24.1M.
Revenue in the twelve months to 30 June 2026: $31.1M. The latest quarter shrank 14.5% year on year.
Net income over the same four quarters: −$35.6M, a −114.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.33.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
Trailing P/E: −2.5×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MaxCyte, Inc. employs 91 people — $341K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MaxCyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MaxCyte announced the appointment of Sidharth Kapileshwar as Chief Corporate Development Officer. The company made the announcement on September 23, 2026.
Why it matters — The appointment adds senior leadership focused on corporate development, which could influence MaxCyte's strategic growth initiatives.
MaxCyte reported that its Compensation Committee granted inducement awards to Sidharth Kapileshwar in connection with his start as Senior Vice-President, Chief Corporate Development Officer. The awards, consisting of stock options for 220,000 shares and a restricted stock unit award for 110,000 shares, were granted under the 2026 Inducement Plan on August 31, 2026, per Nasdaq Listing Rule 5635(c)(4).
Why it matters — MXCT watchers would care because this signals the company's executive hiring incentive structure and a new corporate development leadership addition.
MaxCyte announced the launch of CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service. The assays are designed to provide sensitive identification of off-target sites for adenine and cytosine base editors in genome editing characterization.
Why it matters — The launch expands MaxCyte's SeQure™ service offering by addressing a key gap in genome editing off-target assessment, potentially strengthening its platform for cell therapy development.
MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, due to lower license revenue, instrument placement timing, and prior-year processing assembly purchases. Management said the quarter exceeded its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.
Why it matters — The revenue decline and management's outlook on stabilization and second-half growth are directly relevant to MXCT watchers tracking the company's near-term trajectory.
MaxCyte, Inc. held its Q2 2026 earnings call, during which management discussed the company's financial results and operational performance for the quarter.
Why it matters — This earnings call provides MXCT investors and analysts with direct commentary from management on the company's recent financial health and strategic direction.
The 6 Wall Street analysts covering MaxCyte, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2.43 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering MaxCyte, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MaxCyte, Inc. 75 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, MaxCyte, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +341.2% from the last close, and Ticker Nerd's factor model ranks MaxCyte, Inc. 75 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MaxCyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MXCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.43 to $5 over the next 12 months.
MaxCyte, Inc. returned -40.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development.
The most recent item we track (GlobeNewsWire, 23 Sept 2026): "MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer". MaxCyte announced the appointment of Sidharth Kapileshwar as Chief Corporate Development Officer. The company made the announcement on September 23, 2026.
MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development. MaxCyte designs and commercializes non-viral flow electroporation systems, proprietary processing assemblies, and consumables that help biotechnology and pharmaceutical companies introduce biological cargo into cells with precision and consistency. Its platform is used across drug discovery, translational research, and biomanufacturing, supporting applications in gene editing, immuno-oncology, and other advanced cell-based medicines. The company also offers licensing arrangements tied to partner programs, making its technology part of broader therapeutic development workflows. Headquartered in Rockville, Maryland, MaxCyte serves a global customer base involved in next-generation cell therapeutics and related research.
CEO Mr. Maher Masoud · 91 employees · United States · https://www.maxcyte.com
